THX Pharma (FRA:3VG) EPS without NRI: €-0.25 (TTM As of Dec. 2025)


FRA:3VG THX Pharma FRA:3VG
30 GF Score
Price €3.22
! 1 Warning Sign
View Full Analysis

What is THX Pharma EPS without NRI?

THX Pharma FRA:3VG +1.10% 30 EPS without NRI is €-0.25 as of Dec. 2025. GuruFocus rates FRA:3VG with a GF Score™ of 30/100. The stock has 1 warning sign investors should review. Among 1,177 Biotechnology companies, THX Pharma ranks better than 77.57% on this metric.

THX Pharma's earnings per share without non-recurring items for the six months ended in Dec. 2025 was €-0.14. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.25.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for THX Pharma's EPS without NRI or its related term are showing as below:

FRA:3VG' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -76.7   Med: 5.8   Max: 49
Current: 40.8

FRA:3VG's 3-Year EPS without NRI Growth Rate is ranked better than
77.57% of 1177 companies
in the Biotechnology industry
Industry Median: 16.8 vs FRA:3VG: 40.80

THX Pharma's EPS (Diluted) for the six months ended in Dec. 2025 was €-0.14. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.25.

THX Pharma's EPS (Basic) for the six months ended in Dec. 2025 was €-0.14. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.25.


THX Pharma  (FRA:3VG) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


THX Pharma EPS without NRI Related Terms


THX Pharma EPS without NRI Historical Data

* Premium members only.

The historical data trend for THX Pharma's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

THX Pharma EPS without NRI Chart

THX Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.57 -1.05 -0.84 -0.21 -0.22

THX Pharma Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.39 0.01 -0.21 -0.12 -0.14

FRA:3VG vs VRTX, REGN, ALNY: EPS without NRI Comparison

For the Biotechnology subindustry, THX Pharma's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


THX Pharma PE Ratio without NRI vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, THX Pharma's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where THX Pharma's PE Ratio without NRI falls into.


FRA:3VG
30GF Score
THX Pharma FRA:3VG
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

THX Pharma EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of €-0.25 mean?
THX Pharma (FRA:3VG) has a EPS without NRI of €-0.25 as of Dec. 2025. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on THX Pharma and its competitors. According to the industry distribution chart, THX Pharma ranks #264 out of 1177 companies in the Biotechnology industry, placing it in the top 22.4%.
Is THX Pharma's EPS without NRI too high?
THX Pharma's current EPS without NRI is €-0.25. Based on the distribution chart, THX Pharma ranks #264 out of 1177 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, THX Pharma has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does THX Pharma's EPS without NRI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, THX Pharma ranks #264 out of 1177 companies for EPS without NRI. This places THX Pharma in the top 22% of its industry — outperforming the majority of peers. The industry median EPS without NRI is 16.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Biotechnology company?
The median EPS without NRI among Biotechnology companies is 16.80, based on 1,177 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on THX Pharma and its competitors. For the Biotechnology industry, the median EPS without NRI is 16.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. THX Pharma's current EPS without NRI is €-0.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is THX Pharma stock overvalued right now?
THX Pharma (FRA:3VG) has a current EPS without NRI of €-0.25. The current EPS without NRI is €-0.25. THX Pharma's overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For THX Pharma (FRA:3VG), the current EPS without NRI is €-0.25 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

THX Pharma Business Description

Other Exchanges ALTHX:France3VG:Germany
Address 60 avenue Rockefeller, Pepiniere Laennec, Lyon, FRA, 69008
THX Pharma Formerly Theranexus SA is a France based biopharmaceutical company. It is engaged in developing drug candidates to be used in the treatment of central nervous system (CNS) disorders. The company's therapeutics platform is based on simultaneously targeting neurons and glial cells by creating and developing innovative combinations of two distinct drugs: a CNS drug targeting neuronal activity; and a drug targeting glial cells. The drug candidates of the organization are THN102 to treat excessive daytime sleepiness in Parkinson's disease, THN201 for the treatment of neurocognitive disorders in Alzheimer's disease and THN101 for neuropathic pain.
30GF Score

Get the complete analysis for FRA:3VG

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.22
Price